NCT06349837 2026-05-01Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsSichuan UniversityPhase 1 Recruiting24 enrolled
NCT06762405 2025-02-18PREDIR-NEORECCentre Hospitalier Universitaire DijonPhase 3 Recruiting68 enrolled